vs
奥尼兰姆制药（ALNY）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是奥尼兰姆制药的1.1倍（$1.3B vs $1.2B），奥尼兰姆制药同比增速更快（96.4% vs -5.8%），过去两年奥尼兰姆制药的营收复合增速更高（33.0% vs -6.1%）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
ALNY vs RHI — 直观对比
营收规模更大
RHI
是对方的1.1倍
$1.2B
营收增速更快
ALNY
高出102.2%
-5.8%
两年增速更快
ALNY
近两年复合增速
-6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.3B |
| 净利润 | $206.0M | — |
| 毛利率 | 82.2% | 37.6% |
| 营业利润率 | 23.0% | 1.7% |
| 净利率 | 17.6% | — |
| 营收同比 | 96.4% | -5.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $1.51 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYRHI
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $773.7M | $1.4B | ||
| Q1 25 | $594.2M | $1.4B | ||
| Q4 24 | $593.2M | $1.4B | ||
| Q3 24 | $500.9M | $1.5B | ||
| Q2 24 | $659.8M | $1.5B |
净利润ALNYRHI
| Q1 26 | $206.0M | — | ||
| Q4 25 | $186.4M | — | ||
| Q3 25 | $251.1M | $42.9M | ||
| Q2 25 | $-66.3M | $41.0M | ||
| Q1 25 | $-57.5M | $17.4M | ||
| Q4 24 | $-83.8M | — | ||
| Q3 24 | $-111.6M | $65.5M | ||
| Q2 24 | $-16.9M | $68.2M |
毛利率ALNYRHI
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | 37.6% | ||
| Q3 25 | 84.2% | 37.2% | ||
| Q2 25 | 81.6% | 37.2% | ||
| Q1 25 | 88.2% | 36.9% | ||
| Q4 24 | 82.7% | 38.8% | ||
| Q3 24 | 83.6% | 39.0% | ||
| Q2 24 | 89.8% | 39.2% |
营业利润率ALNYRHI
| Q1 26 | 23.0% | — | ||
| Q4 25 | 12.0% | 1.7% | ||
| Q3 25 | 29.5% | 1.0% | ||
| Q2 25 | -2.1% | 0.1% | ||
| Q1 25 | 3.0% | 2.9% | ||
| Q4 24 | -17.7% | 4.7% | ||
| Q3 24 | -15.4% | 4.1% | ||
| Q2 24 | 7.4% | 5.1% |
净利率ALNYRHI
| Q1 26 | 17.6% | — | ||
| Q4 25 | 17.0% | — | ||
| Q3 25 | 20.1% | 3.2% | ||
| Q2 25 | -8.6% | 3.0% | ||
| Q1 25 | -9.7% | 1.3% | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -22.3% | 4.5% | ||
| Q2 24 | -2.6% | 4.6% |
每股收益（稀释后）ALNYRHI
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | $0.32 | ||
| Q3 25 | $1.84 | $0.43 | ||
| Q2 25 | $-0.51 | $0.41 | ||
| Q1 25 | $-0.44 | $0.17 | ||
| Q4 24 | $-0.66 | $0.53 | ||
| Q3 24 | $-0.87 | $0.64 | ||
| Q2 24 | $-0.13 | $0.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $1.3B |
| 总资产 | $5.1B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALNYRHI
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $464.4M | ||
| Q3 25 | $1.5B | $365.3M | ||
| Q2 25 | $1.1B | $380.5M | ||
| Q1 25 | $1.0B | $342.5M | ||
| Q4 24 | $966.4M | $537.6M | ||
| Q3 24 | $1.1B | $570.5M | ||
| Q2 24 | $968.5M | $547.4M |
股东权益ALNYRHI
| Q1 26 | $1.1B | — | ||
| Q4 25 | $789.2M | $1.3B | ||
| Q3 25 | $233.9M | $1.3B | ||
| Q2 25 | $250.6M | $1.3B | ||
| Q1 25 | $115.4M | $1.3B | ||
| Q4 24 | $67.1M | $1.4B | ||
| Q3 24 | $32.4M | $1.5B | ||
| Q2 24 | $-3.1M | $1.5B |
总资产ALNYRHI
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $2.9B | ||
| Q3 25 | $4.9B | $2.8B | ||
| Q2 25 | $4.6B | $2.8B | ||
| Q1 25 | $4.2B | $2.7B | ||
| Q4 24 | $4.2B | $2.9B | ||
| Q3 24 | $4.2B | $3.0B | ||
| Q2 24 | $4.0B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.5M |
| 自由现金流经营现金流 - 资本支出 | — | $170.8M |
| 自由现金流率自由现金流/营收 | — | 13.1% |
| 资本支出强度资本支出/营收 | — | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $266.8M |
8季度趋势，按日历期对齐
经营现金流ALNYRHI
| Q1 26 | — | — | ||
| Q4 25 | $163.6M | $182.5M | ||
| Q3 25 | $325.1M | $77.4M | ||
| Q2 25 | $153.7M | $119.4M | ||
| Q1 25 | $-118.3M | $-59.3M | ||
| Q4 24 | $-94.7M | $154.8M | ||
| Q3 24 | $43.7M | $129.6M | ||
| Q2 24 | $124.2M | $142.0M |
自由现金流ALNYRHI
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $170.8M | ||
| Q3 25 | $313.0M | $63.6M | ||
| Q2 25 | $139.4M | $104.2M | ||
| Q1 25 | $-127.3M | $-71.7M | ||
| Q4 24 | $-103.8M | $140.5M | ||
| Q3 24 | $39.5M | $111.8M | ||
| Q2 24 | $116.1M | $129.6M |
自由现金流率ALNYRHI
| Q1 26 | — | — | ||
| Q4 25 | 12.8% | 13.1% | ||
| Q3 25 | 25.1% | 4.7% | ||
| Q2 25 | 18.0% | 7.6% | ||
| Q1 25 | -21.4% | -5.3% | ||
| Q4 24 | -17.5% | 10.2% | ||
| Q3 24 | 7.9% | 7.6% | ||
| Q2 24 | 17.6% | 8.8% |
资本支出强度ALNYRHI
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.9% | ||
| Q3 25 | 1.0% | 1.0% | ||
| Q2 25 | 1.8% | 1.1% | ||
| Q1 25 | 1.5% | 0.9% | ||
| Q4 24 | 1.5% | 1.0% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | 1.2% | 0.8% |
现金转化率ALNYRHI
| Q1 26 | — | — | ||
| Q4 25 | 0.88× | — | ||
| Q3 25 | 1.29× | 1.80× | ||
| Q2 25 | — | 2.91× | ||
| Q1 25 | — | -3.42× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
